Technology & AI

Lunit to join Summit Therapeutics on cancer drug AI research

Lunit will support the development of Ibonesimab, a next-generation immuno-cancer drug, alongside U.S. biotech Summit Therapeutics.

By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .

This story is no longer being updated. It reflects reporting up to .

What happened

Lunit will support the development of Ibonesimab, a next-generation immuno-cancer drug, alongside U.S. biotech Summit Therapeutics. The partnership includes AI research aimed at developing new cancer treatments. Lunit's stock hit its daily ceiling during early trading.

Why it matters

The deal extends Lunit's AI work into the development of a new cancer drug.

Coverage

More from Technology & AI

All Technology & AI news · Technology & AI story archive